Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

4D Molecular Therapeutics (FDMT) Receivables - Net (2019 - 2021)

4D Molecular Therapeutics (FDMT) has disclosed Receivables - Net for 3 consecutive years, with $47000.0 as the latest value for Q4 2021.

  • On a quarterly basis, Receivables - Net fell 96.84% to $47000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $47000.0, a 96.84% decrease, with the full-year FY2021 number at $47000.0, down 96.84% from a year prior.
  • Receivables - Net was $47000.0 for Q4 2021 at 4D Molecular Therapeutics, down from $791000.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $1.5 million in Q4 2020 to a low of $47000.0 in Q4 2021.
  • A 3-year average of $825500.0 and a median of $884500.0 in 2019 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: soared 51.94% in 2020, then plummeted 96.84% in 2021.
  • 4D Molecular Therapeutics' Receivables - Net stood at $978000.0 in 2019, then skyrocketed by 51.94% to $1.5 million in 2020, then tumbled by 96.84% to $47000.0 in 2021.
  • Per Business Quant, the three most recent readings for FDMT's Receivables - Net are $47000.0 (Q4 2021), $791000.0 (Q3 2021), and $1.5 million (Q4 2020).